Education
About Us
Working with TipRanks
Follow Us
Progyny (PGNY)
NASDAQ:PGNY
PGNY Stock Chart & Stats
Day’s Range― - ―
52-Week Range$13.39 - $26.76
Previous CloseN/A
Volume466.97K
Average Volume (3M)1.09M
Market Cap
$1.87B
Enterprise Value$1.70B
Total Cash (Recent Filing)$305.09M
Total Debt (Recent Filing)$25.50M
Price to Earnings (P/E)39.2
Beta0.80
Next Earnings
Oct 30, 2025EPS Estimate
0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.19
Shares Outstanding85,982,410
10 Day Avg. Volume1,289,862
30 Day Avg. Volume1,093,429
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.91
Enterprise Value/Revenue1.37
Enterprise Value/Gross Profit6.11
Enterprise Value/Ebitda20.51
Forecast
1Y Price Target
$28.00Price Target Upside24.17% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
Bulls Say, Bears Say
Bulls Say
Analyst RecommendationAnalyst recommends upgrading Progyny from Market Perform to Outperform with a maintained price target, indicating increased confidence in the stock.
EarningsResults came in ahead of expectations and were accompanied by a guidance raise, with the company once again benefiting from favorable utilization.
Financial OutlookPGNY increased 2025 revenue guidance, showing confidence in future growth despite macro uncertainties.
Bears Say
Client ActivityThe number of lives added this selling season is trailing last year's levels.
Client WinsCommentary around lower average lives per client this selling season spurred some questions around new client wins.
Outperformance ConcernsThe lingering question to the pre-announcement would be how much of the outperformance is attributable to extended services for Amazon members which will not continue.
Progyny News
PGNY FAQ
What was Progyny’s price range in the past 12 months?
Progyny lowest stock price was $13.39 and its highest was $26.76 in the past 12 months.
What is Progyny’s market cap?
Progyny’s market cap is $1.87B.
When is Progyny’s upcoming earnings report date?
Progyny’s upcoming earnings report date is Oct 30, 2025 which is in 76 days.
How were Progyny’s earnings last quarter?
Progyny released its earnings results on Aug 07, 2025. The company reported $0.19 earnings per share for the quarter, beating the consensus estimate of $0.158 by $0.032.
Is Progyny overvalued?
According to Wall Street analysts Progyny’s price is currently Undervalued.
Does Progyny pay dividends?
Progyny does not currently pay dividends.
What is Progyny’s EPS estimate?
Progyny’s EPS estimate is 0.13.
How many shares outstanding does Progyny have?
Progyny has 85,982,410 shares outstanding.
What happened to Progyny’s price movement after its last earnings report?
Progyny reported an EPS of $0.19 in its last earnings report, beating expectations of $0.158. Following the earnings report the stock price went down -0.911%.
Which hedge fund is a major shareholder of Progyny?
Currently, no hedge funds are holding shares in PGNY
Progyny Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$28.00 (24.17% Upside)
$28.00 (24.17% Upside)
Blogger Sentiment
Neutral
PGNY Sentiment 50%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 8.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $114.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 1.9%
Last 30 Days <0.1%
Last 30 Days <0.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
6.75%
12-Months-Change
Fundamentals
Return on Equity
10.94%
Trailing 12-Months
Asset Growth
8.92%
Trailing 12-Months
Company Description
Progyny
Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides surrogacy and adoption reimbursement programs for employers. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.
PGNY Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
Progyny's earnings call reflects solid growth and a strong financial performance, highlighted by record ART cycles and increased revenue guidance. The company has successfully retained and expanded client relationships while strategically partnering with industry leaders like Amazon. However, challenges such as slower initial pipeline growth and demographic differences in early client wins present areas to monitor.View all PGNY earnings summariesPGNY Stock 12 Month Forecast
Average Price Target
$28.00
▲(24.17% Upside)
Technical Analysis
Ownership Overview
2.12% Insiders
30.45% Mutual Funds
1.56% Other Institutional Investors
39.62% Public Companies and
Individual Investors